医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

GI Dynamics to Provide Corporate Update and 2017 Third Quarter Results

2017年11月18日 AM06:10
このエントリーをはてなブックマークに追加


 

BOSTON & SYDNEY

GI Dynamics® Inc. (ASX: GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, announces it will provide a corporate update and discuss 2017 third quarter results to investors.

The company will host a webcast at 4 PM EST 21 November 2017 | 8 AM AEDT 22 November 2017.

Accessing the Webcast:

The webcast may be accessed by clicking here or on the GI Dynamics website. The link provided will give you access to view and listen to the webcast on a computer, tablet or mobile device.

For those preferring to listen by telephone, please dial-in five minutes prior to the start of the call. Regional dial-in numbers are as follows:

     

United States (Toll-Free):

877 407 6184
 

United Kingdom (Toll-Free):

0 800 756 3429
 

Germany (Toll-Free):

0 800 182 0040
 

Australia (Toll-Free):

1 800 687 004
 

Switzerland (Toll Free):

800 835 525
 

International (Toll; charges will apply):

201 389 0877
 

The transcript for the call will be available on the company’s website shortly following the webcast.

About GI Dynamics

GI Dynamics, Inc. (ASX:GID) is the developer of EndoBarrier, the first endoscopically delivered device approved for the treatment of type 2 diabetes and obesity. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information, please visit www.gidynamics.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171117005694/en/

CONTACT

Investor Relations
United States:
GI Dynamics, Inc.
Janell
Shields, +1 781-357-3280
investor@gidynamics.com
or
Media
Relations

United Kingdom:
Walbrook PR Ltd
+44 (0)20
7933 8780
GID@walbrookpr.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 一项采用MasimoO3®的前瞻性研究就通气抢救疗法对COVID-19患者脑氧合的效应进行了深入探查
  • City of Hope与Israelita Albert Einstein签署协议以推动拉美地区的癌症治疗
  • Humanigen Announces Closing of Public Offering of Common Stock
  • Masimo O3®を使用してCOVID-19患者の脳酸素化に及ぼす換気補助療法の影響を追究した研究
  • CoVIg-19プラズマ・アライアンス、COVID-19治療薬候補の高度免疫グロブリン製剤を評価するためにNIHが実施した臨床試験のトップライン結果を発表